Teva Takes Tuznue Trastuzumab Biosimilar In Israel From Prestige

Latest Out-Licensing Deal Signed By Prestige BioPharma

 
• By Dean Rudge
Israeli Flag in Jerusalem, israel
Prestige CEO Lisa Park has declared HD201, “The most equivalent biosimilar of Herceptin.” • Source: Shutterstock

More from Biosimilars

More from Products